KSQ-001 is under clinical development by KSQ Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KSQ-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KSQ-001 overview
KSQ-001 is under development for the treatment of PD-1 resistant refractory solid tumors, head and neck squamous cell carcinoma, non-small cell lung cancer and melanoma. It is developed based on CRISPRomics drug discovery engine-genome editing technology. It is administered through intravenous route. The drug candidate consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing.
KSQ Therapeutics overview
KSQ Therapeutics is a drug development company that focuses on the development of novel therapeutics for the treatment of oncology. It treats a wide range of cancers, solid tumors, as well as autoimmune diseases. KSQ Therapeutics serves products under the brand CRISPRomics. The company utilizes CRISPRomics, a functional genomics engine that utilizes a suite of proprietary CRISPR/Cas9 tools to enable high-confidence drug development. Its eTILs carters in revolutionizing the treatment of solid tumors. KSQ Therapeutics is headquartered in Lexington, Massachusetts, the US.
For a complete picture of KSQ-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
